Characterization of RNA aptamers that disrupt the RUNX1–CBFβ/DNA complex

The transcription factor RUNX1 (AML1) is an important regulator of haematopoiesis, and an important fusion partner in leukaemic translocations. High-affinity DNA binding by RUNX1 requires the interaction of the RUNX1 Runt-Homology-Domain (RHD) with the core-binding factor β protein (CBFβ). To generate novel reagents for in vitro and in vivo studies of RUNX1 function, we have selected high-affinity RNA aptamers against a recombinant RHD–CBFβ complex. Selection yielded two sequence families, each dominated by a single consensus sequence. Aptamers from each family disrupt DNA binding by the RUNX1 protein in vitro and compete with sequence-specific dsDNA binding. Minimal, high-affinity (∼100–160 nM) active aptamer fragments 28 and 30 nts in length, consisting of simple short stem-loop structures, were then identified. These bind to the RHD subunit and disrupt its interaction with CBFβ, which is consistent with reduced DNA affinity in the presence of aptamer. These aptamers represent new reagents that target a novel surface on the RHD required to stabilize the recombinant RHD–CBFβ complex and thus will further aid exploring the functions of this key transcription factor.

[1]  L. Roudaia,et al.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity. , 2009, Blood.

[2]  S. Butcher,et al.  DNA mimicry by a high-affinity anti-NF-κB RNA aptamer , 2007, Nucleic acids research.

[3]  S. Radford,et al.  Production and Characterization of RNA Aptamers Specific for Amyloid Fibril Epitopes , 2007, Journal of Biological Chemistry.

[4]  Bruce R Donald,et al.  Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. , 2007, Chemistry & biology.

[5]  Hua Shi,et al.  RNA aptamers directed to discrete functional sites on a single protein structural domain , 2007, Proceedings of the National Academy of Sciences.

[6]  M. Ellingham,et al.  Selection and characterization of RNA aptamers to the RNA-dependent RNA polymerase from foot-and-mouth disease virus. , 2006, RNA.

[7]  H. Nelson,et al.  An RNA aptamer that interferes with the DNA binding of the HSF transcription activator , 2006, Nucleic acids research.

[8]  D. Bunka,et al.  Aptamers come of age – at last , 2006, Nature Reviews Microbiology.

[9]  F. Mikhail,et al.  Normal and transforming functions of RUNX1: A perspective , 2006, Journal of cellular physiology.

[10]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[11]  S. R. Himes,et al.  The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages , 2005, Oncogene.

[12]  G. Morgan,et al.  c-FMS chromatin structure and expression in normal and leukaemic myelopoiesis , 2005, Oncogene.

[13]  Sunjoo Jeong,et al.  Inhibition of the DNA binding by the TCF-1 binding RNA aptamer. , 2005, Biochemical and biophysical research communications.

[14]  L. D. Croce,et al.  Chromatin modifying activity of leukaemia associated fusion proteins. , 2005, Human molecular genetics.

[15]  N. Speck,et al.  Core-binding factors in hematopoiesis and immune function , 2004, Oncogene.

[16]  Jeff Zimmerman,et al.  Crystal structure of NF-κB (p50)2 complexed to a high-affinity RNA aptamer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Morgan,et al.  Epigenetic consequences of AML1–ETO action at the human c‐FMS locus , 2003, The EMBO journal.

[18]  L. Cassiday,et al.  Having it both ways: transcription factors that bind DNA and RNA. , 2002, Nucleic acids research.

[19]  L. Benson,et al.  Binding stoichiometry of an RNA aptamer and its transcription factor target. , 2002, Analytical biochemistry.

[20]  S. Klußmann,et al.  In vivo properties of an anti-GnRH Spiegelmer: An example of an oligonucleotide-based therapeutic substance class , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Speck.  Core binding factor and its role in normal hematopoietic development. , 2001, Current opinion in hematology.

[22]  Jerónimo Bravo,et al.  The leukemia-associated AML1 (Runx1)–CBFβ complex functions as a DNA-induced molecular clamp , 2001, Nature Structural Biology.

[23]  Takashi Kumasaka,et al.  Structural Analyses of DNA Recognition by the AML1/Runx-1 Runt Domain and Its Allosteric Control by CBFβ , 2001, Cell.

[24]  B. Sullenger,et al.  Developing aptamers into therapeutics. , 2000, The Journal of clinical investigation.

[25]  Roger L. Williams,et al.  Structural basis for the heterodimeric interaction between the acute leukaemia‐associated transcription factors AML1 and CBFβ , 2000, The EMBO journal.

[26]  P. Schuck,et al.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. , 2000, Biophysical journal.

[27]  E. Seto,et al.  A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.

[28]  J. Murray,et al.  Secondary Structure Mapping of an RNA Ligand That Has High Affinity for the MetJ Repressor Protein and Interference Modification Analysis of the Protein-RNA Complex* , 1999, The Journal of Biological Chemistry.

[29]  D. Tenen,et al.  Multiple Functional Domains of AML1: PU.1 and C/EBPα Synergize with Different Regions of AML1 , 1998, Molecular and Cellular Biology.

[30]  M. Ohki,et al.  Interaction and functional cooperation of the leukemia‐associated factors AML1 and p300 in myeloid cell differentiation , 1998, The EMBO journal.

[31]  F. Alt,et al.  The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. , 1996, Cell.

[32]  F. Alt,et al.  The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo , 1996, Cell.

[33]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[34]  J. Arnold,et al.  A general purification procedure for chemically synthesized oligoribonucleotides. , 1994, Analytical biochemistry.

[35]  L. Gold,et al.  Selection of high affinity RNA ligands to the bacteriophage R17 coat protein. , 1992, Journal of molecular biology.

[36]  N. Kamada,et al.  Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. , 1991, Blood.

[37]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[38]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[39]  Gerald F. Joyce,et al.  Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA , 1990, Nature.

[40]  L. Cassiday,et al.  Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Arthur J. Rowe,et al.  Analytical ultracentrifugation in biochemistry and polymer science , 1992 .

[42]  麻生 博也.  Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation , 1992 .